Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

The Truth About Cancer Treatment Choices

3 Oct 2025 · 1 min

Watch on YouTube

0:52

In this presentation, the speaker critiques the conventional oncology approach that selects treatment regimens solely based on cancer type and stage, arguing that such average‑based protocols ignore the extensive molecular heterogeneity present even among tumors of the same type and stage. By highlighting that each cancer possesses a unique molecular fingerprint—potentially involving thousands of markers—the speaker explains why standard protocols can lead to inaccurate predictions of treatment response. The core message urges patients and clinicians to focus on precise molecular targeting, asking whether a treatment has been effective in other patients sharing the same molecular profile.

Chapters

So let's start with the conventional oncology conversation. Basically, let's translate what you're going to hear often. We're choosing the regimen that works for your cancer type and your stage of cancer. That sounds reasonable. It also is average based clinical trial groups patients by tumors by type and stage, but not by the multiple personal precision molecular fingerprints. And here's why that's a problem. No two cancers are the same. You can have two breast cancers, same type and stage. When you do the heterogeneity and the testing, you're going to see they're so different. Their heterogeneicity means are super different. When you look at a thousand markers, they're not the same cancer anymore and their targets are going to work differently and their response is going to be different. So when someone's telling you, here's what our response is with a general protocol, it's not as accurate as you need it to be. The real question you need an answer to is how precise is your treatment targeting and have you seen anybody with all my molecular targets and how have they responded?